0001628280-26-030947
SEC filingA breakout revenue quarter defined by surging Rezdiffra demand was overshadowed by aggressive commercial and pipeline investment, widening operating losses and accelerating cash burn as the company scales its MASH franchise.
Madrigal's Q1 2026 results capture the classic profile of a commercial-stage biopharma in aggressive expansion mode: revenue is scaling rapidly, but the cost structure is expanding even faster as management invests to capture the MASH market opportunity.
Revenue increased 127% to $311.3 million, driven by increased demand for Rezdiffra in the United States. The company is demonstrating commercial viability as the first-to-market therapy for MASH. Cost of sales increased primarily due to higher royalties payable to Roche, reflecting the direct correlation between revenue growth and variable costs under the company's licensing arrangements. Management expects cost of sales to increase in future periods as manufacturing costs incurred prior to regulatory approval—which were previously expensed to research and development—are now reflected in inventory costs following approval.
Operating loss widened to -$92.7 million from -$79.3 million in the prior year period, representing an operating margin of -29.8%. The expanded loss reflects the substantial investment required to build commercial infrastructure and advance pipeline development. Net income of -$94.4 million compares to -$73.2 million in Q1 2025, indicating the company is in a deep investment phase. The decrease in interest income due to lower interest rates compared to the corresponding period in 2025 also contributed to the wider net loss.
Free cash flow was -$171.3 million, with operating cash burn nearly doubling year-over-year to -$167.4 million. Capital expenditures of $3.8 million represent a new baseline compared to minimal spending in the prior year. The acceleration in cash deployment underscores the capital-intensive nature of launching a first-in-class therapy while simultaneously advancing clinical programs. Management noted that current tariff policies are not expected to have a material impact on operations, as U.S. commercial supply is manufactured domestically.
The filing reveals a company at an inflection point: Rezdiffra is demonstrating commercial traction, but the path to profitability requires sustained revenue growth while managing the cash demands of pipeline development and market expansion. Management indicated that until the company is able to generate sufficient revenue from Rezdiffra and any other future approved products, it anticipates continuing to incur losses. Key catalysts include outcomes data from the MAESTRO-NASH trial expected in 2028 and MAESTRO-NASH OUTCOMES results in 2027, which could support full FDA approval and expand the eligible patient population to include compensated MASH cirrhosis patients.